Johnson & Johnson pauses COVID-19 vaccine trials due to sick subject

After a participant in one of its coronavirus vaccine trials became sick with an unexplained illness, manufacturer Johnson & Johnson announced Monday that it has suspended its COVID-19 vaccine investigations. An independent data-safety monitoring board is now reviewing the case to determine if the complication is tied to the study intervention.

After a participant in one of its coronavirus vaccine trials became sick with an unexplained illness, manufacturer Johnson & Johnson announced Monday that it has suspended its COVID-19 vaccine investigations. An independent data-safety monitoring board is now reviewing the case to determine if the complication is tied to the study intervention. If the experts find a correlation, safety concerns could potentially derail the candidate vaccine, which is one of the most advanced currently under development. A Phase III trial with as many as 60,000 volunteers launched last month, with hopes of results rolling in as soon as the end of this year and regulatory clearance for use in early 2021. The pause in dosing with the J&J vaccine, which it developed in collaboration with Boston's Beth Israel Deaconess Medical Center, comes after AstraZeneca twice had to put its trials on hold to make sure serious adverse events were not linked to its vaccine.